We do not plan to make material changes to our fair value estimate for the narrow-moat financial services firm.
The wide-moat firm had a solid third quarter, and we are increasing our fair value estimate to $114.
We don't see any major impact to our fair value estimate based on the quarter's outperformance.
UnitedHealth shows momentum, but we do not expect to change our fair value estimate for the wide-moat firm.
We're reducing fair value estimate for the narrow-moat firm.
The narrow-moat firm is reducing commissions on U.S.-listed equities, ETFs, and options to $0.
We expect to decrease our fair value estimate for wide-moat Charles Schwab amid news of its pricing cut.
We still view at least one or two more cuts over the next year as the most likely outcome.
The $572 million payment amount for Johnson & Johnson is lower than expected, and the wide-moat firm plans to appeal the case.
We continue to recommend investing in this 4-star narrow-moat company.
We still believe shares of the no-moat firm offer a significant margin of safety.
The wide-moat firm is preparing for its transformational leap into direct to consumer with the launch of Disney+ in November.
We are leaving our fair value estimate in place for the wide-moat firm.
We view shares of the wide-moat firm as attractive.
We recommend prospective investors steer clear of shares at current levels.
We are incorporating three rate cuts (including this one) through 2020 into our bank forecasts.
Despite the risks posed by the 737 MAX groundings, GE maintained its long-term industrial free cash flow outlook in the quarter.
We're maintaining our $200 fair value estimate.
We do not expect to change our fair value estimate for the no-moat firm.
We like what we're seeing from the wide-moat firm but think it's overvalued.
While this is a setback for Capital One, investors should view it as an opportunity to purchase the shares at a discount.
We maintain our no-moat rating and await additional details on the Pfizer transaction.
The divestment of the generics business should strengthen Pfizer's competitive positioning.
We view Amazon as one of the most attractive names in online commerce.
We are maintaining our $1,300 per share fair value estimate on this wide-moat name.
Second-quarter results for the wide-moat firm were ahead of our expectations.
Our fair value estimate remains in place unless market sentiment becomes too negative.
We recommend waiting for some margin of safety before investing in this high uncertainty name.
We are not changing our fair value estimate for the no-moat automaker.
The narrow-moat firm delivered solid wireless results during the second quarter.
The wide-moat firm remains a safe harbor in a sea of rich software valuations.
We are retaining our narrow moat rating and our fair value estimate of $135.
Management's focus on innovation and brand investments has led to improved performance.
We're positive on the acquisition and are maintaining our current fair value estimate on Cisco for now.
We are leaving our U.S. autos coverage fair value estimates in place, because the tariff will face major pushback from lawmakers.
Uber Technologies is the leader in the ride-sharing market in the U.S.
First-quarter revenue increased 3.8% to $60.7 billion, more or less in line with our forecast.
The release put slowing household spending in the spotlight, supporting the case that the economic picture remains mixed.
We are maintaining our fair value estimate, and we think shares are fairly valued at current levels.
Berkshire Hathaway puts some cash to work with a $10 billion pledge.
We're planning to increase our $2,200 fair value estimate for the wide-moat firm.
We think investors with a long-term horizon will find current levels compelling relative to our unchanged fair value estimate of $65 per share.
We are giving Tesla the benefit of the doubt and maintaining our fair value estimate.
We recommend waiting for a pullback before investing in this wide-moat name.
Solid revenue upside drove better margins for the wide-moat firm.
We're launching coverage of the online product and idea discovery company with a narrow economic moat and a $22 fair value estimate.
The first-quarter performance reinforces our wide moat rating.
Profitability is improving, but growth isn't perfect yet.
We plan to modestly lift our fair value estimate but think full earnings potential may be constrained by pricing competition.
The IPO price is in line with our fair value estimate, and we would recommend a wider margin of safety before investing in this very high uncertainty name.